HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

AGMB — AgomAb Therapeutics NV

AGMB (AgomAb Therapeutics NV) stock: $7.63, $376.0M market cap, $0.0M cash, $376.0M EV, $485.3M fully diluted market cap. Data from Fully Diluted's biotech stocks database.

What they do

Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities.

Source: 20-F FY2025 via SEC EDGAR

Share price
$7.63
Market cap
$376.0M
Cash
$0.0M
Enterprise value
$376.0M

Balance sheet

Cash$0.0M
Debt$0.0M
Net cash$0.0M
Enterprise value$376.0M
Basic shares49.2M shares
Fully diluted shares63.6M shares
Fully diluted market cap$485.3M
Cash per share$0.00

Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.

Share structure

Common
59.9M
Pre-funded warrants
0.0M
Options
3.7M
RSUs
0.0M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
63.6M

Cap table as of 2026-03-04.

Price history

Loading AGMB daily closes…

Loading price history…

Recently reported

ontunisertib Phase 2a Positive · 2026-10-01
STENOVA · fibrostenosing Crohn's disease
Source release →
AGMB-447 Phase 1 Positive · 2026-09-14
idiopathic pulmonary fibrosis
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.
Subscribe to Compounding Ego